No Data
No Data
Prius: 2024 Semi-Annual Report
Prius: 2024 Semi-Annual Report Summary
Puresis (301257.SZ) announced its performance for the first half of the year, with a net income of 54.923 million yuan, a decrease of 11.33% year-on-year.
Pures (301257.SZ) released the semi-annual report for 2024, with the company achieving revenue of 3....
As of July 31, 2024, the total number of shareholders in Puresis (301257.SZ) is 8,784.
On August 5th, Gelunhui reported that as of the close of July 31, 2024, there were 8,784 shareholders in the company according to Pruce's announcement on the investors' interactive platform.
PURUISI (301257.SZ): Received the proposal for the mid-2024 dividend from the company's actual controlling shareholder and director.
On July 18th, Gr8est7i (301257.SZ) announced that in order to promote the shared operating development benefits for all shareholders, and practice the development concept of "investors first" based on long-term confidence in the company's development, enhance investor return levels, promote high-quality development of listed companies, and effectively protect the interests of the vast number of investors, the company's 2023 Annual Shareholders' Meeting has been held on May 20, 2024, and has approved the proposal of "Requesting the Board of Directors to Authorize the Mid-Term Dividend Plan". The company agrees to pay a mid-term dividend for the year 2024 while meeting the conditions for profit distribution.
Puruisi (301257.SZ): main customers are international pharmaceutical companies or well-known domestic innovative pharmaceutical companies.
Prussia (301257.SZ) stated on the investor interaction platform on June 27th that its main customers are international pharmaceutical companies or well-known domestic innovative pharmaceutical companies. As one of the earliest companies to enter the SMO industry in China, the company has become a qualified supplier for many well-known domestic and foreign pharmaceutical companies and CRO clients such as Novo Nordisk, Merck, Roche, Mandy, Abbott, Pfizer, Johnson & Johnson, Lilly, Jingding, Bayer, GlaxoSmithKline, AstraZeneca, Fuqirui, Hengrui, Kangfang, and Zhongda Tianqing, thanks to its professional service capabilities.
No Data
No Data